skip to cookie settings skip to content
BridgeBio
  • About
  • Science
  • Pipeline
    • Attruby®

      (acoramidis)

      ↗
    • NULIBRY®

      (fosdenopterin)

      ↗
  • Patients
News
Careers
Investors

Latest

Sidebar content postList

  • All

PUBLICATION · Jan 2024

The New England Journal of Medicine, Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

PRESENTATION · Dec 2023 · PDF

Acoramidis - AHA 2023 - Clinical Outcome Improvements

PRESENTATION · Dec 2023 · PDF

Infigratinib - ESPE 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study

PRESENTATION · Dec 2023 · PDF

ADH1 - ASHG 2023 Novel Variants of the CaSR

PRESENTATION · Dec 2023 · PDF

BBP-418 - WMS 2023 - Phase 2 Data at 21 Months; Ambulatory Improvements at 9 Months

PRESENTATION · Dec 2023 · PDF

Canavan GTx BBP-812 - Neurology for Science 2023 - CANaspire Phase 1/2 Study

PRESENTATION · Dec 2023 · PDF

Acoramidis - October 2023 - 4 Year Update from OLE Phase 2 Study

PRESENTATION · Dec 2023 · PDF

Infigratinib - ENDO 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study

PRESENTATION · Dec 2023 · PDF

Encaleret - ADH1 - ASBMR 2023 Mineral Normalization in Phase 2b

PRESENTATION · Dec 2023 · PDF

BBP-418 for LGMD2I/R9 - MDA 2023 - Oral Presentation - Phase 2 Data at 15 Months

  • Previous Page
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Next Page

Breaking news for the achondroplasia community

Positive Topline Phase 3 Data from PROPEL 3, our Study of Oral Infigratinib
Read Press Release

Stay informed.

Company

  • About Us
  • Careers
  • Investors ↗
  • Contact Us

Insights

  • On Rare Podcast ↗
  • News ↗

Science

  • Clinical Trial Info
  • Presentations & Publications
  • Grants & Funding

Medicines & Pipeline

  • Pipeline
  • Attruby® (acoramidis) ↗
  • NULIBRY® (fosdenopterin) ↗

Patients

  • Stories
  • Access
  • Support

Policies

  • Terms of Use
  • Global Privacy Policy
  • Cookies Settings
  • All Policies

Social

  • LinkedIn ↗
  • X ↗
  • Facebook ↗
  • Instagram ↗
  • YouTube ↗
  • TikTok ↗
BridgeBio

This site is intended for U.S. residents.

BridgeBio, Attruby, the Attruby logo, ForgingBridges, and the ForgingBridges logo are trademarks of BridgeBio Pharma, Inc. All other trademarks are property of their respective owners.

© 2026 BridgeBio Pharma, Inc. All rights reserved.